Skye Pharma and Kos Life Sciences Enters Exclusive Agreement for US Marketing and Distribution of Flutiform
The strategic partnership includes an upfront licensing payment of $25 million. If all regulatory and sales milestones are met, SkyePharma could receive up to an additional $140 million in payments, plus mid-teens sales royalties.
Kos and Skye are sponsoring a conference call on May 8, 1330 BST/ 0830 EDT, discussing the details of the license agreement. A replay will also be available on Kos' or SkyePharma's websites until 2359 EDT on Friday, May 12, 2006.
Source: Kos Pharma
.jpg)
Comment Preview